NCT00193609 - Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

April 30, 2008

Study Completion Date

January 31, 2009

Conditions

Neoplasms, Unknown Primary

Interventions

DRUG

Oxaliplatin

130 mg/m2 IV day 1 of 21 day cycle

DRUG

Capecitabine

1000 mg/m2 by mouth twice daily on days 1-14 of each 21 day cycle

Trial Locations (10)

Reading Hospital Regional Cancer Center, West Reading

Spartanburg Regional Medical Center, Spartanburg

Integrated Community Oncology Network, Jacksonville

Tennessee Oncology, PLLC, Nashville

Chattanooga Oncology Hematology Associates, Chattanooga

Consultants in Blood Disorders and Cancer, Louisville

Greenview Regional Hospital, Bowling Green

Oncology Hematology Care, Cincinnati

AP&S Oncology & Hematology Northside, Terre Haute

Baton Rouge General Medical Center, Baton Rouge